Trial
NCT04019288
AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
M.D. Anderson Cancer Center
Collaborators
Aravive Biologics Inc; AstraZeneca
Condition
Platinum-Resistant Fallopian Tube Carcinoma
Intervention
Batiraxcept
Why stopped
PI Request
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-06-11